Observed Signal · Sep 28, 2026 · Product Launch · Source: AbbVie

U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease

Executive Signal Summary

The U.S. FDA approved AbbVie's JUVMO (tavapadon) on September 28, 2026, as the first and only selective D1/D5 receptor agonist for adults with Parkinson's disease. The approval is based on Phase 3 TEMPO data showing significant improvements in daily functioning, increased "on" time without troublesome dyskinesia, and a favorable safety profile. AbbVie expects to make JUVMO available to U.S. patients in October 2026.

Polaris7 AgentPolaris7 Strategic Assessment
High Confidence

This approval introduces the first selective D1/D5 receptor agonist for Parkinson's disease, offering a new mechanism of action that may reduce the tradeoffs associated with current D2/D3 agonists. It is strategically significant for AbbVie's neuroscience portfolio and for the broader Parkinson's treatment landscape, given the high unmet need for alternatives to levodopa dose escalation.

MARKET SIGNALS

Track AbbVie Signals & Strategic Shifts

Polaris7 connects regulatory filings, primary sources, leadership changes, and M&A activity into structured intelligence. Set up your Polaris7 workspace to monitor relevant companies in your executive briefing.

  • Verified primary sources
  • Automated briefings
  • Instant watchlist setup

Key Takeaways & Evidence Grounding

  • The U.S. FDA approved AbbVie's JUVMO (tavapadon) on September 28, 2026, as the first and only selective D1/D5 receptor agonist for adults with Parkinson's disease.
  • The approval was supported by Phase 3 TEMPO clinical trial data (TEMPO-1, TEMPO-2, TEMPO-3, and TEMPO-4).
  • JUVMO is taken once daily with or without levodopa therapy and is available in 5 mg, 10 mg, and 15 mg tablets plus a Titration Pack containing 0.25 mg and 1 mg tablets.
  • AbbVie expects to make JUVMO available to patients in the U.S. in October 2026.
  • More than 11 million people worldwide live with Parkinson's disease, and about 70% of patients increase their oral levodopa dose within the first year of therapy.

Connected Companies & Entities

“AbbVie is the pharmaceutical company that developed JUVMO (tavapadon) and announced the FDA approval on September 28, 2026.”

Primary Source Grounding & Direct Attribution
Direct Origin Attribution
Primary Reporting: AbbVie•Published: Sep 28, 2026

Related Market Signals & Shifts

Recent verified developments and strategic activity across this market segment.

Leadership & PeopleNov 2, 2026

AbbVie Director Jennifer L. Davis Resigns Following Align Technology CEO Appointment

On October 28, 2026, Jennifer L. Davis, a Class II director of AbbVie Inc., notified the Board of Directors of her intent to resign, effective November 2, 2026. The resignation is directly attributable to her recent appointment as Chief Executive Officer at Align Technology, Inc. The company explicitly confirmed that her departure does not stem from any dispute or disagreement regarding AbbVie's operations, policies, or practices.

Read assessment
Leadership & PeopleOct 15, 2026

AbbVie Expands Board of Directors to Thirteen Members with Appointment of Dr. John M. Carethers

On October 14, 2026, AbbVie Inc. enlarged its Board of Directors from twelve to thirteen members and appointed Dr. John M. Carethers as an independent Class II director. Dr. Carethers currently serves as the Vice Chancellor for Health Sciences at the University of California San Diego and brings previous corporate governance experience as a director at Avantor, Inc. Alongside his board appointment, Dr. Carethers has been named to AbbVie's Public Policy and Sustainability Committee, receiving standard independent director compensation.

Read assessment
Product & Platform LaunchOct 5, 2026

AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival...

Read assessment

WATCHLIST & BRIEFINGS

Receive future signals for AbbVie & competitors in your briefing

Stay ahead of material M&A deals, leadership changes, account wins, and product rollouts. Polaris7 connects primary filings, company newsrooms, and trade reporting directly into your executive briefing.

  • Regular primary-source checks
  • Structured Watchlist briefings
  • Preserves current context